Comparison
Ecnoglutide vs. Efinopegdutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
no data
2055640-93-0
Molecular weight
no data
no data
Half-life
144 h
115 h
Sequence
no data
modifiziertes, von Oxyntomodulin abgeleitetes Peptid, konjugiert an ein humanes IgG4-Fragment (Verlängerung der Plasma-Halbwertszeit)Mechanism of action
Ecnoglutide
Ecnoglutide is a modified GLP-1(7-37) peptide with an alanine-to-valine substitution at position 8 and an 18-C fatty-acid conjugation at the lysine-30 side chain. It is a so-called biased agonist: at the GLP-1 receptor it preferentially induces cAMP formation while β-arrestin recruitment is reduced. In preclinical models this has been linked to lower receptor internalisation and desensitisation. GLP-1 receptor activation is mechanistically associated with enhanced glucose-dependent insulin secretion, delayed gastric emptying and satiety signalling. The fatty-acid conjugation enables weekly administration via albumin binding.
Efinopegdutide
Efinopegdutide is an oxyntomodulin-derived peptide acting as a dual agonist at the GLP-1 and glucagon receptors with a relative potency of approximately 2:1 (GLP-1 to glucagon). The GLP-1 component mediates glucose-dependent insulin secretion and modulation of satiety; the glucagon component increases energy expenditure and hepatic fat oxidation, which is proposed to contribute to the observed reduction in liver fat. Conjugation to an IgG4 fragment prolongs the half-life and enables weekly administration.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
3
of which in humans
5
3
Effects recorded
4
4
Open conflicts
0
1
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Ecnoglutide and Efinopegdutide?
- Ecnoglutide is classified as "Metabolic", while Efinopegdutide is classified as "Metabolic". Ecnoglutide: Ecnoglutide (XW003) is a long-acting, cAMP-signalling-biased GLP-1 analogue from Sciwind Biosciences. Derived from GLP-1(7-37) with an alanine-to-valine substitution at position 8, it activates the GLP-1 receptor selectively via the cAMP pathway over β-arrestin recruitment. Investigated for weight management and in type 2 diabetes. Efinopegdutide: Efinopegdutide (MK-6024, formerly JNJ-64565111 / HM12525A) is a once-weekly dual agonist at the GLP-1 and glucagon receptors, developed by Hanmi and Merck. It has been studied for obesity and notably for metabolic liver disease (MASH/NAFLD); a phase-2 trial showed greater liver-fat reduction than semaglutide. Investigational, not approved. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Ecnoglutide or Efinopegdutide?
- The highest available evidence level is "Human RCT" for Ecnoglutide and "Human RCT" for Efinopegdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Ecnoglutide and Efinopegdutide in Germany and the United States?
- Germany: Ecnoglutide — Unapproved, Efinopegdutide — Unapproved. United States: Ecnoglutide — Unapproved, Efinopegdutide — Unapproved. These are factual summaries with source and review date on the individual pages.